Quatrx Licenses Women's Health Drug to Shionogi in $125M Deal March 3, 2010 By Catherine Hollingsworth
Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal Feb. 23, 2010 By Catherine Hollingsworth Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. (BioWorld Today)Read More
Aryx Shares Take a Hard Fall as Advanced Partner Talks Dissolve Feb. 22, 2010 By Catherine Hollingsworth
Discovery Labs Hopes to Beef Up Cash with $16.5M Stock Offering Feb. 19, 2010 By Catherine Hollingsworth
